Dry Eye Disease 

  • Dry Eye affects over 35% of the population aged 50+, with women representing approximately two-thirds of those affected
  • Worldwide, ~700 M patients suffer from dry eye disease
  • Several side effects and modest efficacy of currently available drugs demand new therapies to treat dry eye disease
  • Huge potential for new drugs for a $5 Billion dry eye market

OK-101 Drug Candidate 

  • Inflammation and pain are the most common symptoms of dry eye
  • OK-101 is a novel class of chemerin receptor agonist that produces an anti-inflammatory action and reduction in neuropathic pain
  • Inclusion of a lipid ‘anchor’ within the OK-101 drug molecule is designed to decrease washout due to tearing and blinking, and to enhance the ocular residence time of OK-101

Rapid Clinical Development 

  • IND submission planned for Q3/Q4 2022
  • Able to skip Phase 1 safety trial and go directly to Phase 2 safety and efficacy trial in dry eye disease patients
  • Phase 2 trial in dry eye disease patients anticipated to start in Q4 2022
  • Topline data expected in Q2/Q3, 2023